Phibro Animal Health Corp. (PAHC) News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{
  "main_header": {
    "sid": 1159124,
    "name": "Phibro Animal Health Corp.",
    "stock_name": "Phibro Animal Health Corp.",
    "full_name": "Phibro Animal Health Corp.",
    "name_url": "stocks-analysis/phibro-animal-health-corp",
    "exchange": 210,
    "exchangecode": "NAS",
    "country_id": 2,
    "currency": "USD",
    "cmp": "40.77",
    "chg": 0.09,
    "chgp": "0.22%",
    "dir": 1,
    "prev_price": "40.68",
    "mcapval": "1,598.24",
    "mcap": "Small Cap",
    "scripcode": "",
    "symbol": "",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 2305,
    "indexname": "S&P 500",
    "isin": "US71742Q1067",
    "curr_date": "Dec 04",
    "curr_time": "",
    "bse_nse_vol": "513.85 k",
    "exc_status": "Active",
    "traded_date": "Dec 04, 2025",
    "traded_date_str": "2025 12 04",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-registerF-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/phibro-animal-health-corp-1159124-210&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Phibro Animal Health Corp. Experiences Revision in Its Stock Evaluation Amid Strong Performance",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/phibro-animal-health-corp-sees-valuation-grade-downgrade-from-very-attractive-to-fair-3686250",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/PhibroAnimalHea_valuationdot_3686250.png",
        "date": "2025-11-10 15:54:59",
        "description": "Phibro Animal Health Corp. has recently adjusted its valuation, with its stock price at $43.76. Over the past year, the company has achieved an impressive 86.21% return, significantly outperforming the S&P 500. Key financial metrics indicate a strong competitive position within the Pharmaceuticals & Biotechnology sector."
      },
      {
        "title": "Phibro Animal Health Corp. Hits New 52-Week High at $44.35",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/phibro-animal-health-corp-hits-new-52-week-high-at-4435-3671479",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/PhibroAnimalHea_priceRelatedfactors_3671479.png",
        "date": "2025-11-04 17:49:00",
        "description": "Phibro Animal Health Corp. achieved a new 52-week high, reflecting its strong performance in the Pharmaceuticals & Biotechnology sector. The company has shown significant growth, impressive financial metrics, and consistent positive results over recent quarters, solidifying its market position and appealing to income-focused investors."
      },
      {
        "title": "Phibro Animal Health Corp. Hits New 52-Week High of $43.65",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/phibro-animal-health-corp-hits-new-52-week-high-of-4365-3667267",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/PhibroAnimalHea_priceRelatedfactors_3667267.png",
        "date": "2025-11-03 17:03:55",
        "description": "Phibro Animal Health Corp. achieved a new 52-week high on October 31, 2025, reflecting its strong performance in the pharmaceuticals and biotechnology sector. The company has shown significant growth over the past year, with impressive financial metrics and consistent positive results across multiple quarters."
      },
      {
        "title": "Phibro Animal Health Corp. Hits New 52-Week High of $42.80",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/phibro-animal-health-corp-hits-new-52-week-high-of-4280-3649234",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/10/PhibroAnimalHea_priceRelatedfactors_3649234.png",
        "date": "2025-10-27 16:48:13",
        "description": "Phibro Animal Health Corp. achieved a new 52-week high on October 24, 2025, reflecting its strong performance in the Pharmaceuticals & Biotechnology sector. The company has shown impressive growth over the past year, with significant increases in stock value, net profit, and solid financial metrics, including a high return on equity."
      },
      {
        "title": "Is Phibro Animal Health Corp. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-phibro-animal-health-corp-overvalued-or-undervalued-3637731",
        "imagepath": "",
        "date": "2025-10-21 12:07:54",
        "description": "As of 17 October 2025, the valuation grade for Phibro Animal Health Corp. has moved from very attractive to attractive, indicating a shift in perception. The company appears to be fairly valued based on its current metrics. Key ratios include a P/E ratio of 21, an EV to EBITDA of 9.97, and a PEG ratio of 0.12, which suggests that the stock is reasonably priced relative to its growth potential.\n\nWhen compared to peers, Phibro Animal Health Corp. has a P/E of 29.58, which is significantly higher than the negative P/E ratios of its risky counterparts like Soleno Therapeutics, Inc. and Arcutis Biotherapeutics, Inc. Additionally, the company has demonstrated strong returns, with a year-to-date return of 89.14% compared to the S&P 500's 13.30%, reinforcing the attractiveness of its valuation...."
      },
      {
        "title": "Phibro Animal Health Corp. Experiences Revision in Its Stock Evaluation Amid Strong Performance",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/phibro-animal-health-corp-valuation-grade-downgraded-from-very-attractive-to-attractive-3640868",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/10/PhibroAnimalHea_valuationdot_3640868.png",
        "date": "2025-10-20 16:44:55",
        "description": "Phibro Animal Health Corp., a small-cap in the Pharmaceuticals and Biotechnology sector, has adjusted its valuation metrics, showing a P/E ratio of 21 and a low PEG ratio of 0.12. The company has outperformed the S&P 500 significantly in year-to-date and annual returns, indicating a stable market position."
      },
      {
        "title": "Is Phibro Animal Health Corp. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-phibro-animal-health-corp-overvalued-or-undervalued-3634601",
        "imagepath": "",
        "date": "2025-10-20 12:25:22",
        "description": "As of 17 October 2025, the valuation grade for Phibro Animal Health Corp. has moved from very attractive to attractive, indicating a shift in perceived value. The company appears to be fairly valued based on its current metrics, with a P/E ratio of 21, a Price to Book Value of 3.67, and an EV to EBITDA of 9.97. In comparison to its peers, Phibro's valuation is more favorable than Soleno Therapeutics, Inc., which has a P/E of -21.86, and Arcutis Biotherapeutics, Inc., with a P/E of -22.20.\n\nPhibro has demonstrated strong performance, with a year-to-date return of 89.14% compared to the S&P 500's 13.30%, and a one-year return of 63.05% against the S&P 500's 14.08%. These figures suggest that the stock is performing well relative to the broader market, reinforcing the notion that it is fairly valued at this time...."
      },
      {
        "title": "Is Phibro Animal Health Corp. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-phibro-animal-health-corp-overvalued-or-undervalued-3632139",
        "imagepath": "",
        "date": "2025-10-19 12:02:54",
        "description": "As of 17 October 2025, the valuation grade for Phibro Animal Health Corp. has moved from very attractive to attractive, indicating a shift in perception. The company appears to be fairly valued based on its current metrics. Key valuation ratios include a P/E ratio of 21, an EV to EBITDA of 9.97, and a PEG ratio of 0.12, which suggests that the stock is reasonably priced relative to its growth potential.\n\nIn comparison to its peers, Phibro Animal Health Corp. has a more favorable valuation with a PEG ratio of 0.12, while Soleno Therapeutics, Inc. and Arcutis Biotherapeutics, Inc. are both considered risky with negative P/E ratios. The stock has outperformed the S&P 500 with a year-to-date return of 89.14% compared to the index's 13.30%, reinforcing the notion that it is fairly valued in the current market context...."
      },
      {
        "title": "Is Phibro Animal Health Corp. technically bullish or bearish?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-phibro-animal-health-corp-technically-bullish-or-bearish-3545726",
        "imagepath": "",
        "date": "2025-09-20 19:17:07",
        "description": "As of 7 August 2025, the technical trend for Phibro Animal Health Corp. has changed from mildly bullish to bullish. The current stance is bullish with strong indicators supporting this view. The MACD is bullish on both weekly and monthly time frames, and Bollinger Bands also indicate a bullish trend in both periods. Daily moving averages are bullish, while the KST shows bullish momentum on both weekly and monthly charts. However, the OBV is mildly bullish weekly but mildly bearish monthly, suggesting some divergence in volume trends.\n\nIn terms of performance, Phibro has significantly outperformed the S&P 500 across multiple periods, with a year-to-date return of 93.05% compared to the S&P 500's 12.22%, and a one-year return of 83.02% versus 17.14%. Overall, the technical indicators point to a strong bullish stance for the stock...."
      }
    ],
    "total": 16,
    "sid": "1159124",
    "stock_news_url": "https://www.marketsmojo.com/news/phibro-animal-health-corp-1159124"
  },
  "announcements": "",
  "corporate_actions": {
    "msg": "No corporate action Found"
  }
}

News and Views

Phibro Animal Health Corp. Experiences Revision in Its Stock Evaluation Amid Strong Performance

2025-11-10 15:54:59

Phibro Animal Health Corp. has recently adjusted its valuation, with its stock price at $43.76. Over the past year, the company has achieved an impressive 86.21% return, significantly outperforming the S&P 500. Key financial metrics indicate a strong competitive position within the Pharmaceuticals & Biotechnology sector.

Phibro Animal Health Corp. Hits New 52-Week High at $44.35

2025-11-04 17:49:00

Phibro Animal Health Corp. achieved a new 52-week high, reflecting its strong performance in the Pharmaceuticals & Biotechnology sector. The company has shown significant growth, impressive financial metrics, and consistent positive results over recent quarters, solidifying its market position and appealing to income-focused investors.

Phibro Animal Health Corp. Hits New 52-Week High of $43.65

2025-11-03 17:03:55

Phibro Animal Health Corp. achieved a new 52-week high on October 31, 2025, reflecting its strong performance in the pharmaceuticals and biotechnology sector. The company has shown significant growth over the past year, with impressive financial metrics and consistent positive results across multiple quarters.

Phibro Animal Health Corp. Hits New 52-Week High of $42.80

2025-10-27 16:48:13

Phibro Animal Health Corp. achieved a new 52-week high on October 24, 2025, reflecting its strong performance in the Pharmaceuticals & Biotechnology sector. The company has shown impressive growth over the past year, with significant increases in stock value, net profit, and solid financial metrics, including a high return on equity.

Is Phibro Animal Health Corp. overvalued or undervalued?

2025-10-21 12:07:54

As of 17 October 2025, the valuation grade for Phibro Animal Health Corp. has moved from very attractive to attractive, indicating a shift in perception. The company appears to be fairly valued based on its current metrics. Key ratios include a P/E ratio of 21, an EV to EBITDA of 9.97, and a PEG ratio of 0.12, which suggests that the stock is reasonably priced relative to its growth potential. When compared to peers, Phibro Animal Health Corp. has a P/E of 29.58, which is significantly higher than the negative P/E ratios of its risky counterparts like Soleno Therapeutics, Inc. and Arcutis Biotherapeutics, Inc. Additionally, the company has demonstrated strong returns, with a year-to-date return of 89.14% compared to the S&P 500's 13.30%, reinforcing the attractiveness of its valuation....

Phibro Animal Health Corp. Experiences Revision in Its Stock Evaluation Amid Strong Performance

2025-10-20 16:44:55

Phibro Animal Health Corp., a small-cap in the Pharmaceuticals and Biotechnology sector, has adjusted its valuation metrics, showing a P/E ratio of 21 and a low PEG ratio of 0.12. The company has outperformed the S&P 500 significantly in year-to-date and annual returns, indicating a stable market position.

Is Phibro Animal Health Corp. overvalued or undervalued?

2025-10-20 12:25:22

As of 17 October 2025, the valuation grade for Phibro Animal Health Corp. has moved from very attractive to attractive, indicating a shift in perceived value. The company appears to be fairly valued based on its current metrics, with a P/E ratio of 21, a Price to Book Value of 3.67, and an EV to EBITDA of 9.97. In comparison to its peers, Phibro's valuation is more favorable than Soleno Therapeutics, Inc., which has a P/E of -21.86, and Arcutis Biotherapeutics, Inc., with a P/E of -22.20. Phibro has demonstrated strong performance, with a year-to-date return of 89.14% compared to the S&P 500's 13.30%, and a one-year return of 63.05% against the S&P 500's 14.08%. These figures suggest that the stock is performing well relative to the broader market, reinforcing the notion that it is fairly valued at this time....

Is Phibro Animal Health Corp. overvalued or undervalued?

2025-10-19 12:02:54

As of 17 October 2025, the valuation grade for Phibro Animal Health Corp. has moved from very attractive to attractive, indicating a shift in perception. The company appears to be fairly valued based on its current metrics. Key valuation ratios include a P/E ratio of 21, an EV to EBITDA of 9.97, and a PEG ratio of 0.12, which suggests that the stock is reasonably priced relative to its growth potential. In comparison to its peers, Phibro Animal Health Corp. has a more favorable valuation with a PEG ratio of 0.12, while Soleno Therapeutics, Inc. and Arcutis Biotherapeutics, Inc. are both considered risky with negative P/E ratios. The stock has outperformed the S&P 500 with a year-to-date return of 89.14% compared to the index's 13.30%, reinforcing the notion that it is fairly valued in the current market context....

Is Phibro Animal Health Corp. technically bullish or bearish?

2025-09-20 19:17:07

As of 7 August 2025, the technical trend for Phibro Animal Health Corp. has changed from mildly bullish to bullish. The current stance is bullish with strong indicators supporting this view. The MACD is bullish on both weekly and monthly time frames, and Bollinger Bands also indicate a bullish trend in both periods. Daily moving averages are bullish, while the KST shows bullish momentum on both weekly and monthly charts. However, the OBV is mildly bullish weekly but mildly bearish monthly, suggesting some divergence in volume trends. In terms of performance, Phibro has significantly outperformed the S&P 500 across multiple periods, with a year-to-date return of 93.05% compared to the S&P 500's 12.22%, and a one-year return of 83.02% versus 17.14%. Overall, the technical indicators point to a strong bullish stance for the stock....

View All News